Medicover

210.00 SEK

-1.41 %

Less than 1K followers

MCOV B

NASDAQ Stockholm

Health Care Providers

Health Care

-1.41 %
+4.48 %
-3.45 %
-4.76 %
-7.08 %
-13.40 %
+20.34 %
-10.06 %
+220.61 %

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Read more
Market cap
32.24B SEK
Turnover
6.36M SEK
Revenue
25.69B
EBIT %
6.55 %
P/E
37.82
Dividend yield-%
1.03 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.7
2026

Interim report Q2'26

4.11
2026

Interim report Q3'26

ShowingAll content types
Third party research

Medicover: Stronger than the weather - ABG

* Strong Q1 beat with 110bps margin expansion on adj. EBITDA * Adj. EBITDA up 1% for '26e-'28e on Q1 beat * FVR unchanged at SEK 190-270 on minor estimate revisions A solid start to '26 despite weather drag Q1 was 8%/6% above ABGSCe/Infront consensus...

Medicover

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Medicover: Model proves itself in Q1 - ABG

* 8%/6% adj. EBITDA vs ABGSCe/Infront cons in Q1 * Cons estimates likely up 1-3% on adj. EBITDA '26e * Model proved itself despite the weather headwind we flagged Q1 results Medicover reported a strong start to '26 with sales in-line vs cons and a clear...

Medicover
Third party research

Medicover: Weather is set to be a drag - ABG

* Q1'26 numbers due on 29 April at 07:45 CET * Near-term caution, but the model should continue to prove itself * Fair value range down to SEK 190-270 (200-280) Q1'26 should be marked by cold weather We expect colder-than-usual temperatures and severe...

Medicover
Third party research

Medicover: From build-out to fill-up - ABG

* Focus on sport/wellness, dental and smaller centres * Adj. EBITDAaL margin expansion: 11.7% to 12.9% during '26e-'28e * ~25% below its historical average on NTM EV/EBITDA Polish capex skewing to margin-accretive growth levers Last Wednesday we visited...

Medicover
Third party research

Medicover: Path to 2028 explained - ABG

* Expanding margins on the back of a maturing asset base * A clear and differentiated strategy for each of the four core markets * Join us for our 4 March site visit in Warsaw (RSVP link below) From expansion to utilisation and margin delivery The key...

Medicover
Third party research

Medicover: A promising trajectory - ABG

* A solid report and new targets underpin long-term case * Adj. EBITDA largely unchanged for '26e-'27e, sales slightly down * We now expect a 15% adj. EBITDA CAGR '25-'28e Solid Q4 closes a strong year Q4 was in line with estimates and confirmed the ...

Medicover
Third party research

Medicover: New targets confirm the long-term story - ABG

* 0%/-3% adj. EBITDA vs ABGSCe/Infront cons in Q4 * Cons estimates likely flat on adj. EBITDA '26e, up mid-term * New targets 9% above ABGSCe target expectation on earnings Q4 results Medicover reported a solid Q4 with sales in-line and a small miss ...

Medicover

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.